Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan

• Published in: Cancer medicine (Malden, MA) MA), 2024-09, Vol.13 (18), p.e70249-n/a
• Main Authors: Kunimasa, Kei, Sugimoto, Naotoshi, Yamasaki, Tomoyuki, Kukita, Yoji, Fujisawa, Fumie, Inoue, Tazuko, Yamaguchi, Yuko, Kitasaka, Mitsuko, Sakai, Daisuke, Honma, Keiichiro, Wakamatsu, Toru, Yamamoto, Sachiko, Hayashi, Takuji, Mabuchi, Seiji, Okuno, Jun, Kawamura, Takahisa, Kai, Yugo, Urabe, Makiko, Nishimura, Kazuo
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Bile ducts; Biomarkers, Tumor - genetics; Cancer; Clinical medicine; clinical trial; Clinical trials; comprehensive genomic profiling; Consent; Drug therapy; Female; Genetic counseling; Genomes; genomically matched therapy; Genomics; Genomics - methods; Humans; Japan; Male; Melanoma; Middle Aged; Mutation; Neoplasms - genetics; Neoplasms - therapy; Patients; Precision medicine; Precision Medicine - methods; Progression-Free Survival; real world data; Sarcoma; solid tumor; Solid tumors; Treatment Outcome; Young Adult
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.70249

Introduction Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real‐world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and its effectiveness. Methods We analyzed data from advanced solid tumor patients who underwent CGP panel between December 2019 and May 2023 at the Osaka International Cancer Institute. Patient demographics, specimen details, and expert panel assessments were collected. Turnaround time (TAT) and genomically matched therapy outcomes were analyzed. Gene alterations and their co‐occurrence patterns were also assessed. Results Among 1437 patients, 1096 results were available for analysis. The median TAT was 63 [28–182] days. There were 667 (60.9%) cases wherein recommended clinical trials were presented and there were 12 (1.1%) cases that could be enrolled in the trial and 25 (2.3%) cases that could lead to therapies under insurance reimbursement. The median progression free survival of the trial treatment was 1.58 months (95% CI: 0.66–4.37) in clinical trials and 3.66 months (95% CI: 2.14–7.13) in treatment under insurance. Pathologic germline variants were confirmed in 15 patients (1.3%). Co‐alteration of CDKN2A, CDKN2B, and MTAP was significantly observed in overall population. Conclusion The effectiveness of the genomically matched therapy based on the CGP panel was unsatisfactory. Expansion of clinical trials and utilization of remote clinical trials are required to ensure that the results of the CGP panel can be fully returned to patients. The effectiveness of the genomically matched therapy based on the CGP panel was unsatisfactory. Expansion of clinical trials and utilization of remote clinical trials are required to ensure that the results of the CGP panel can be fully returned to patients.